Unbundling Pharmacy Benefits: Why Your PBM Contract Is Your Biggest Opportunity for Health Plan Cost Containment in 2026

For many employers, pharmacy benefit spending has quietly become the fastest-growing and least understood segment of their overall group health insurance costs. While medical claims still represent the largest share of total spend, pharmacy trends are rising at two to three times the pace of medical inflation—driven primarily by specialty drugs, biologics, gene therapies, and opaque payment mechanisms buried deep inside traditional PBM (Pharmacy Benefit Manager) contracts.

As we move into 2026, one reality is becoming increasingly clear for employers:
Your PBM contract may represent the single largest opportunity for immediate and sustainable health plan cost containment.

The reason? Most employer pharmacy programs remain built on “bundled” PBM pricing models, where formularies, rebates, dispensing fees, mail order fulfillment, specialty pharmacy distribution, and reporting are managed under one massive contract structure—often lacking transparency, accountability, and flexibility. These models make it extremely difficult for employers to determine what medications truly cost, where margin is being generated, and how much rebate revenue is actually reaching the plan.

This is where unbundling pharmacy benefits is gaining traction.

Unbundling allows employers to separate pharmacy services—claims processing, formulary management, network contracting, specialty pharmacy sourcing, and rebate collection—into distinct vendor arrangements that offer greater transparency, pricing control, competitive bidding, and customization.

In this guide, we will break down what unbundled PBM strategies look like, why they are accelerating in adoption, how employers can evaluate their PBM contracts, and what steps are needed to unlock meaningful pharmacy savings for 2026 and beyond.

The Pharmacy Cost Crisis

Pharmacy spending now accounts for 20–30% of total health plan costs for many employer groups, but its growth rate remains the greatest concern. Key cost drivers include:

• Specialty medications treating conditions such as cancer, MS, rheumatoid arthritis, and rare diseases—which can exceed $100,000 per patient annually

• High-cost injectables and biologics

• Brand-name price inflation often exceeding standard CPI

• Gene therapies launching at multi-million-dollar price points

Yet despite these enormous financial stakes, pharmacy is the portion of the health plan where employers typically have the least financial visibility.

Why?

Because most PBM contracts are engineered around revenue spread—not transparency.

Why Traditional PBM Contracts Are So Expensive

Under the traditional bundled PBM model, the PBM controls nearly every element of the pharmacy supply chain:

• Network pharmacy contracting

• Claims adjudication platforms

• Specialty pharmacy fulfillment

• Mail-order services

• Manufacturer rebate negotiations

• Data reporting

Instead of charging employers straightforward administrative fees, bundled PBMs generate revenue through multiple indirect streams, including:

Spread Pricing

PBMs charge employers more than they reimburse pharmacies and keep the difference—often hidden inside claims data.

Retained Rebates

While employers believe rebates reduce net drug costs, many PBMs:

• Retain undisclosed portions of manufacturer rebates

• Apply rebates to offset premium equivalents rather than directly lowering claims

• Aggregate employer rebates without transparent allocation

Specialty Pharmacy Markups

PBM-owned specialty pharmacies purchase drugs at heavily discounted rates yet bill plan sponsors at rates far exceeding acquisition cost.

Channel Steering

PBMs direct employees toward their own mail-order or specialty facilities to preserve margin—sometimes at the expense of continuity of care or cost-effectiveness.

All of these income sources are deeply embedded into bundled contracts, obscured by confusing pricing structures and incomplete reporting. As a result:

• Employers cannot validate net drug cost benchmarks.

• Pharmacy trends appear uncontrollable despite contract “discounts.”

• Rebates fail to meaningfully reduce total pharmacy spend.

What Is Pharmacy Benefit Unbundling?

Unbundling pharmacy benefits means removing these bundled PBM revenue layers and outsourcing each service component to vendors who operate under full transparency pricing.

Instead of one monolithic PBM agreement, employers migrate to:

• A transparent claims processing administrator

• Separate competitive pharmacy networks

• Independent rebate aggregators who pass 100% of rebates back to the plan

• Open specialty pharmacy networks using lowest net-cost sourcing

This modular approach allows each segment to be competitively bid—and continuously optimized—eliminating hidden spread profit and reclaiming employer purchasing power.

The Core Components of an Unbundled PBM Strategy

Employers evaluating unbundling should understand the functional components of pharmacy administration:

1. Claims Processing Platform

The PBM function that:

• Receives pharmacy claims

• Applies formulary coverage logic

• Calculates copays and deductible accumulators

In unbundled models, these platforms operate on flat administrative fees, eliminating margin incentives.

2. Pharmacy Network Contracting

Rather than exclusive PBM pharmacy networks, employers gain open access networks, allowing:

• Direct negotiations with high-volume pharmacies

• Performance-based pharmacy contracting

• Maximum competitive pressure on dispensing fees

3. Rebate Contracting

Independent rebate aggregators negotiate directly with manufacturers and can:

• Pass through 100% of rebate dollars

• Provide detailed rebate transparency

• Align rebate structures with employer formularies instead of PBM profit formulas

4. Specialty Pharmacy Sourcing

Open specialty models allow employers to:

• Utilize multiple specialty pharmacies

• Secure drugs at actual acquisition cost rather than inflated PBM markups

• Avoid exclusive arrangements unnecessarily locking patients into higher-cost fulfillment systems

5. Clinical Formulary Management

Employers can customize formularies to emphasize:

• Biosimilar adoption

• Cost-effective therapeutic alternatives

• Value-based medication tiers for chronic conditions

Clinical oversight remains in employer control—not directed by PBM profit incentives.

Why Unbundling Is Accelerating Among Employers

Employers adopting unbundled pharmacy benefit strategies are doing so to solve three long-standing problems.

1. Transparency

Employers finally gain clear insight into:

• Unit drug acquisition costs

• Contracted pharmacy reimbursements

• Total rebates earned

• True net medication pricing

Without transparency, strategic pharmacy management is impossible.

2. Purchasing Power

Separate vendor bidding allows employers to:

• Renegotiate each contract component independently

• Re-benchmark vendor performance year-over-year

• Remove complacent pricing arrangements

This restores true purchasing leverage long eroded by massive PBM consolidation.

3. Cost Trend Control

Transparency vendors enable proactive formulary and specialty management strategies, not reactive rebate chasing after claims soar.

Employers can manage:

• High-cost pipeline medications

• Biosimilar transitions

• Utilization management protocols

In bundled PBM structures, employers are often forced to accept trends rather than influence them.

How Much Can Employers Save?

Savings vary based on group size and specialty drug exposure, but typical unbundling strategies achieve:

• 7–15% immediate pharmacy cost reductions

• Larger reductions for high-specialty populations

• Elimination of spread pricing leakages

• Direct utilization of full rebate pass-through

Critically, these savings are structural, not one-time concessions. Employers retain ongoing negotiating leverage as drug trends evolve.

How to Evaluate Your PBM Contract for 2026

Before pursuing any pharmacy restructuring, employers must perform a thorough PBM contract audit. Key steps include:

1. Analyze Your Effective Discount Rates

Ask:

• What average ingredient cost discount am I actually receiving?

• How do those rates compare to NADAC benchmarks?

• Is spread pricing still present?

Many employers believe they receive strong retail discounts—yet spread analysis often reveals inflated claim pricing.

2. Rebate Transparency Review

Employers should demand:

• Line-item rebate contracts

• Full rebate validation audits

• Clear pass-through language

If your PBM cannot or will not demonstrate 100% rebate transparency, opportunities are likely being missed.

3. Specialty Drug Contract Assessment

Specialty pharmacy margins often exceed those of retail claims by a wide margin.

Employers should evaluate:

• Acquisition cost comparisons

• Exclusive channel steering impact

• Alternative sourcing networks

4. Data and Reporting Access

High-quality pharmacy analytics must include:

• Claim-level details

• Drug mix and pipeline projections

• Clinical intervention opportunity analyses

Opaque or summary reporting prevents effective decision-making.

5. Operational Readiness Review

Not every employer is immediately ready for full unbundling. Employers need:

• HR teams capable of managing vendor relationships

• Administrative workflows for managing specialty transitions

• Employee education capabilities

Some employers may benefit from phased adoption or partial transparency models first.

Risks and Considerations of Unbundling

While unbundling delivers significant value, employers must consider operational factors:

1. Vendor Coordination Complexity

Managing multiple pharmacy vendors requires oversight and integration support—typically coordinated through an experienced employee benefits advisor.

2. Change Management

Employees must be educated on:

• Pharmacy network changes

• Specialty pharmacy sourcing transitions

• Potential new medication utilization rules

Communication ensures continuity of care during implementation.

3. Vendor Due Diligence

Not all “transparent PBMs” offer true transparency.

Employers must validate:

• Actual pricing methodologies

• Rebate pass-through guarantees

• Ownership conflicts

Superficial transparency still carries risk if vendors retain hidden revenue streams.

Why 2026 Is the Key Inflection Point

Several market forces make 2026 an ideal year for employers to reassess PBM strategies:

Specialty Drug Explosion

Gene therapies, oncology pipelines, and new biologics will accelerate pharmacy spend rapidly. Without true cost oversight, medical costs will follow suit.

Employer Fiduciary Pressure

Under ERISA fiduciary standards, employers increasingly face legal obligations to actively evaluate healthcare contract value—not passively renew costly arrangements.

Vendor transparency now intersects directly with fiduciary responsibility.

Competitive Labor Market

Employers need benefits programs that preserve healthcare access without passing costs to employees via higher premiums and deductibles.

Transparency savings allow benefits preservation while controlling budgets.

How Taylor Benefits Insurance Agency Helps Employers Navigate PBM Unbundling

Evaluating pharmacy unbundling demands deep contractual, clinical, and data analysis expertise, far beyond basic benefits brokerage services.

Taylor Benefits Insurance Agency works with employers to:

• Audit existing PBM contracts for hidden costs and revenue flows

• Perform rebate and spread pricing validation analyses

• Construct side-by-side bundled vs unbundled cost models

• Identify transparent PBM platforms and specialty networks

• Manage vendor RFP processes and contract negotiations

• Develop employee education strategies for smooth transitions

By combining pharmacy analytics with holistic group health insurance advising, Taylor Benefits ensures employers achieve legitimate savings while safeguarding employee access to life-saving medications.

Final Thoughts

Unbundling pharmacy benefits represents the most powerful(and underutilized) cost-containment strategy for employer health plans heading into 2026. Traditional PBM contracts, while familiar, are laden with structural inefficiencies and hidden revenue flows that no longer serve employers or employees.

Transparent, modular pharmacy benefit strategies provide real control over specialty drug trends, rebate recovery, and formulary optimization without sacrificing care quality.

For organizations committed to sustainable healthcare financing, pharmacy unbundling isn’t simply another renewal alternative, it is the next evolution of benefits stewardship.

With expert guidance from Taylor Benefits Insurance Agency, employers can reclaim visibility, purchasing power, and financial predictability—positioning their benefits programs for stability in an increasingly volatile healthcare marketplace.